Who gains from more information on the quality of pharmaceutical drugs? Are there incentives for voluntary post-approval clinical trials among pharmaceutical companies? Contrary to popular belief, this paper shows that it is not in the consumer interest that clinical evidence establishing the...

A class of self-designing clinical trials is considered which according to an effective but simple, finite learning algorithm consists of automatically adaptively planned weighted group sequential trials with a decision about rejection of the null-hypothesis at each step, but the full...

Rewarding inventors with inefficient monopoly power has long been regarded as the price of encouraging innovation. Public prescription drug insurance escapes that trade-off and achieves an elusive goal: lowering static deadweight loss, while simultaneously encouraging dynamic investments in...